Rapid Profiling of Bone Marrow, at Presentation and After 5 Days of Induction Therapy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2011 by Rambam Health Care Campus.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT01268800
First received: December 30, 2010
Last updated: July 20, 2011
Last verified: June 2011
  Purpose

Personalization of AML therapy, require a reliable mechanism for accurate characterization of patient specific leukemia phenotype and genotype. Patient's specific leukemic phenotype or in practical clinical term, patient's leukemia sensitivity to induction therapy, should best investigated in-vivo during induction. Elimination of circulating leukemic blasts from peripheral blood by day 5 was shown to discriminate between good responders with superior long term survival and poor responders with poor outcome. However, many AML patients have no circulating blasts at diagnosis and even in those who have, elimination rate of it from peripheral blood was never correlated with actual response in bone marrow.

Currently, the only available source for patient's specific leukemia profile, is the bone marrow sample at diagnosis. Since leukemic blasts are heterogeneous and come from multiple different clones, "on diagnosis" marrow consist a spectrum of chemotherapy sensitive and resistance clones. Clones may vary by their molecular abnormalities and results from "on diagnosis" marrow may overlook minor resistant but existing clones. Long term prognosis is determined by those resistant clones and though our interests should be focused into the abnormalities of these clones. Residual blasts on day 5 marrow may better represent the profile of patient's leukemic resistant clones.


Condition
AML

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Rapid Profiling of Bone Marrow, at Presentation and After 5 Days of Induction Therapy, a Sensitive Method for Identifying Resistant AML Clones

Further study details as provided by Rambam Health Care Campus:

Biospecimen Retention:   Samples With DNA

Blood bone marrow and buccal smear


Estimated Enrollment: 50
Study Start Date: February 2011
Groups/Cohorts
AML induction
Adults AML patients who were referred for intensive induction therapy

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Adults (>18) AML patients

Criteria

Inclusion Criteria:

  • Diagnosis of acute myeloid leukemia other than APL
  • Age > 18
  • Patient's considered by their physician "fit" for intensive induction therapy

Exclusion Criteria:

  • Withdrawal of informed consent or inability to consent
  • Previous allogeneic transplantation.
  • One of the following lab values persistent from presentation to day 5:

    • Serum creatinine > 2mg/dl, Direct bilirubin > 2mg/dl
    • SGOT (AST) > x4 upper limit of normal
    • Left ventricular ejection fraction < 40% as assessed 2-D echocardiogram
    • Coagulation abnormalities (INR > 1.6, PTT > x1.5 normal range)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01268800

Contacts
Contact: Yishai ofran, MD 972-4-5842541 y_ofran@rambam.health.gov.il

Locations
Israel
Rambam medical center Recruiting
Haifa, Israel, 31096
Contact: Yishai Ofran, MD    972-4-8542541    y_ofran@rambam.health.gov.il   
Principal Investigator: Yishai Ofran, MD         
Sponsors and Collaborators
Rambam Health Care Campus
Investigators
Principal Investigator: Yishai Ofran, MD Rambam Health Care Campus
  More Information

No publications provided

Responsible Party: Dr Yishai Ofran, Rambam medical center
ClinicalTrials.gov Identifier: NCT01268800     History of Changes
Other Study ID Numbers: 0588-10-rmb-CTIL
Study First Received: December 30, 2010
Last Updated: July 20, 2011
Health Authority: Israel: Ethics Commission

Keywords provided by Rambam Health Care Campus:
AML
Induction

ClinicalTrials.gov processed this record on April 17, 2014